Engulfing Line (Bullish)
|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||36.93 - 37.85|
|52 Week Range||31.45 - 115.33|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||16.29|
|Earnings Date||Aug 28, 2023 - Sep 01, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.25|
Subscribe to Yahoo Finance Plus to view Fair Value for CTLTLearn more
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Catalent (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials.
Catalent (NYSE: CTLT) investors are clearly an optimistic bunch, as lately they've been taking not-so-bad-news very positively and trading up the stock. JPMorgan Chase's (NYSE: JPM) Julia Qin was the person behind the downgrade. Catalent has been a troubled company of late, and caution is clearly warranted.
Here is your Pro Recap of the biggest analyst cuts you may have missed today: downgrades for Nike, Foot Locker, Canadian National Railway, and Catalent. Nike (NYSE:NKE) shares fell more than 1% pre-market today after Williams Trading downgraded the company to Sell from Hold with a price target of $95.00. According to the firm, the downgrade move was predicated on Nike’s U.S. business, which it says will remain "challenged" through at least the first half of fiscal 2024, and due to a lack of new compelling products, consumers may be becoming trained to look for promotions.
U.S. equities declined on Friday, May 19, 2023 as GOP negotiators called for a pause in talks to raise the federal debt ceiling.
Catalent shares jumped after the contract drug maker said customer supplies are strong and it's getting "significant" new business.
Contract drug manufacturer Catalent (ticker: CTLT) delivered more bad news on Friday, but investors shrugged it off, securing the stock a top place in the S&P 500. The company said it will [again be delaying the release of earnings](https://www.
Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter report for a second time. It seems counterintuitive that Catalent, after downgrading guidance and saying it was not able to prepare third-quarter earnings on time, would go up in price. The company's shares had already fallen when it announced on May 8 that its earnings report and guidance would not be on May 9, as originally scheduled.
Catalent's financials are still past due, but investors are looking forward. The pharmaceuticals contract manufacturer said Friday it is unable to file its financial results with the SEC for the fiscal third quarter, which ended in March. Investors did get some-much needed clarity on the company’s full-year outlook.
Catalent Inc (NYSE: CTLT) lowered its 2023 revenue and profit forecast, reflecting operational challenges and higher-than-expected costs and delaying its Q3 FY23 earnings release twice this month. The company expects FY23 sales of $4.25-$4.35 billion compared with its prior forecast of $4.63-$4.88 billion and the consensus of $4.35 billion. Catalent said it now sees adjusted net income of $187-$228 million, down from the previous forecast of $567- $648 million. The company continues to win signi
Yahoo Finance markets contributor Remy Blaire breaks down the morning market action while also taking a look at shares of Foot Locker and Catalent.
Catalent reduces fiscal 2023 revenue guidance but says its customer supply situation remains 'healthy' and that it continues to 'win significant new business.'
Catalent Inc cut its full-year net revenue and profit forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to both its annual sales and core profit expectations earlier this month. The company manufactures drugs, vaccines and gene therapies at 55 different sites for major pharmaceutical companies, including Moderna Inc, Novo Nordisk and Sarepta Therapeutics, among others. Catalent said it continues to win significant new business, including the expansion of supply agreements with Novo Nordisk, and added its customer supply situation remains healthy.
(Reuters) -Contract drug manufacturer Catalent Inc on Friday slashed its full-year forecasts for profit and sales and delayed its quarterly results for the third time, bruised by a series of missteps at its major production facilities. Shares of the company reversed their premarket declines and rose 13% to $36.24 as the new guidance looks more achievable than their previous one, according to KeyBanc Capital markets analyst Paul Knight. Catalent, one of the top contract manufacturers for pharmaceutical companies, said a drop in revenue from COVID vaccine manufacturing had coincided with higher-than-expected costs and production challenges at its facilities in Indiana and in Brussels.
Catalent Inc cut its full-year net revenue forecast on Friday, reflecting operational challenges and higher-than-expected costs after it flagged an over $400 million hit to both its annual sales and core profit forecasts earlier this month. The contract drug manufacturer now sees its full-year revenue in the range of $4.25 billion to $4.35 billion compared with its prior forecast of $4.63 billion to $4.88 billion. Catalent manufactures drugs, vaccines and gene therapies at 55 different sites for major pharmaceutical companies, including Moderna Inc's COVID-19 vaccine, Novo Nordisk's weight-loss drug Wegovy and Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD).
SOMERSET, N.J., May 19, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the "Form 12b-25") with the Securities and Exchange Commission (the "SEC"); the Company’s ongoing focus on finalizing its financial statements and other disclosures in its
Investing.com -- Stocks in focus in premarket trade on Friday, May 19th. Please refresh for updates.
SOMERSET, N.J., May 13, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company’s ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended
The out-of-favor contract drug manufacturer saw two analysts get notably less bullish on its future.
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Shares dropped more than 25% on Monday after the company delayed its Q3 earnings announcement (expects on May 15, previously scheduled on May 9) and said it expects to cut its full-year outlook. Needham downgraded Green Dot (NYSE:GDOT) to Hold from Buy following the company’s reported Q1 results on Thursday. Wolfe Research downgraded Qualys (NASDAQ:QLYS) to Underperform from Peerperform with a price target of $100.00 following last week’s Q1 beat.
U.S. equities indexes were little changed on Monday, May 8, 2023, with crucial reports on inflation expected later in the week.
The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update, and in response traded the shares down by almost 26% on the day. In its press release on the matter, Catalent said that the delay stems from its discovery of certain noncash adjustments connected with its operations in Bloomington, Indiana.
Carnival led S&P 500 stocks Monday as optimism continues for cruise lines. AMD surged above an early buy point. Catalent was a big loser.